BMC Cancer最新文献

{"title":"TRPM2 channels mediate ROS-induced actin remodeling and cell migration of prostate cancer cells.","authors":"Pengwei Qi, Jingting Zhao, Hongtian Zhang, Xingyu Liu, Qing You, Jianguo Niu, Xiangming Ye, Fangfang Li","doi":"10.1186/s12885-025-14333-3","DOIUrl":"https://doi.org/10.1186/s12885-025-14333-3","url":null,"abstract":"<p><strong>Background: </strong>Actin remodeling plays important roles in pathophysiological processes such as cancer metastasis and angiogenesis. Reactive oxygen species (ROS) are signaling molecules thought to regulate cell migration by remodeling actin cytoskeleton. Earlier, we demonstrated that Transient receptor potential melastatin 2 (TRPM2) channels mediates H₂O₂-induced actin remodeling and cell migration in HeLa cells by manipulating Ca²⁺ and Zn²⁺. However, the mechanism by which ROS produced in models more relevant to pathophysiological circumstances affect the actin cytoskeleton, remains poorly unknown. Therefore, this study aimed to explore the effect of ROS produced from pathophysiological conditions on actin cytoskeleton and cell migration. And then investigates the role of TRPM2 channels in the regulation of these types of ROS-induced actin remodeling and cell migration in prostate cancer cells.</p><p><strong>Methods: </strong>The study utilized various molecular probes, reagents, and cell culture techniques. Prostate cancer (PC)-3 and DU145 cell line were cultured and treated with different compounds to induce ROS production and actin remodeling. The actin cytoskeleton was stained with phalloidin or labelled with pActin-tdTomato plasmid and imaged using confocal microscopy. Zn²⁺ and Ca²⁺ levels were measured by Fluozin3-AM and Fluo4-AM probes respectively. Cell migration as-says were performed to assess the role of TRPM2 channels.</p><p><strong>Results: </strong>We demonstrated that both H₂O₂ and palmitate induces TRPM2-dependent elevation of cytosolic Ca²⁺ and Zn²⁺, leading to actin remodeling both in PC-3 and DU145 cells. Inhibition or knockdown of TRPM2 channels or chelation of Zn²⁺ significantly reduced these effects.</p><p><strong>Conclusions: </strong>TRPM2 channels and TRPM2-mediated Zn²⁺ are essential in ROS-induced actin remodeling and cell migration in prostate cancer cells. Preventing TRPM2 channel activation and chelating Zn²⁺ may offer potential therapeutic strategies for preventing cancer metastasis. Further research is needed to identify molecular targets of Zn²⁺ in the actin cytoskeleton and cancer cell migration.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"956"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-year follow-up of atypical small acinar hyperplasia cases diagnosed by initial prostate biopsy.","authors":"Rui Su, Shi-Jie Ye, Su-Ying Wang, Zhou-Liang Zhang, Hui-Ping Chen, Hui-Zhi Zhang, Chang Li, Ming Zhao, Xin Fei, Ze-Jun Yan, Qi Ma","doi":"10.1186/s12885-025-14366-8","DOIUrl":"https://doi.org/10.1186/s12885-025-14366-8","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical outcomes and diagnostic strategies for patients with atypical small acinar hyperplasia (ASAP) in their initial prostate biopsy in a real-world setting.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the data of 170 patients who received their first prostate biopsy result as ASAP. The lost follow-up rate, clinical interventions, subsequent pathological results, prostate cancer detection rate, and Gleason scores were analyzed. Furthermore, subgroup analysis was performed on cases with repeat biopsies.</p><p><strong>Results: </strong>Of the 170 patients, 45 were lost to follow-up, with a dropout rate of 26.5%. Among the remaining 125 patients, 68 did not receive clinical intervention. Meanwhile, 57 underwent clinical interventions during follow-up, including 50 with repeat biopsies (50 second-time biopsies, 8 third-time biopsies, and 2 fourth-time biopsies), 3 underwent transurethral resection of prostate (TURP), and 4 had radical surgeries. In total, 28 were diagnosed with prostate cancer, diagnoses included 22 cases from prostate biopsies, 2 from TURP, and 4 from radical surgeries. Of the 22 biopsy-confirmed prostate cancer cases, 17 underwent radical surgeries at our hospital. Postoperative pathology revealed that 71.4%(5/7) of the cases upgraded from clinically insignificant cancer to clinically significant cancer. Ultimately, clinically significant prostate cancer accounted for 85.7%(24/28) of all positive cases and 42.1%(24/57) of the clinically intervened cases. Further subgroup analysis revealed that biopsy groups 6-12 months post-initial ASAP diagnosis had a noticeably higher positive rate than those biopsied within 6 months.</p><p><strong>Conclusion: </strong>For the patients with ASAP diagnosed by the initial biopsy, the risk of subsequent diagnosis of clinically significant prostate cancer is high. Combined with the high dropout rate and postoperative pathological escalation rate in this study cohort, it is recommended that patients with ASAP be given high priority in clinical practice, and repeated biopsy is recommended to be carried out within 6-12 months.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"964"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating SEResNet101 and SE-VGG19 for advanced cervical lesion detection: a step forward in precision oncology.","authors":"Yan Ye, Yuanyuan Chen, Jiajia Pan, Peipei Li, Feifei Ni, Haizhen He","doi":"10.1186/s12885-025-14353-z","DOIUrl":"https://doi.org/10.1186/s12885-025-14353-z","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer remains a significant global health issue, with accurate differentiation between low-grade (LSIL) and high-grade squamous intraepithelial lesions (HSIL) crucial for effective screening and management. Current methods, such as Pap smears and HPV testing, often fall short in sensitivity and specificity. Deep learning models hold the potential to enhance the accuracy of cervical cancer screening but require thorough evaluation to ascertain their practical utility.</p><p><strong>Methods: </strong>This study compares the performance of two advanced deep learning models, SEResNet101 and SE-VGG19, in classifying cervical lesions using a dataset of 3,305 high-quality colposcopy images. We assessed the models based on their accuracy, sensitivity, specificity, and area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>The SEResNet101 model demonstrated superior performance over SE-VGG19 across all evaluated metrics. Specifically, SEResNet101 achieved a sensitivity of 95%, a specificity of 97%, and an AUC of 0.98, compared to 89% sensitivity, 93% specificity, and an AUC of 0.94 for SE-VGG19. These findings suggest that SEResNet101 could significantly reduce both over- and under-treatment rates by enhancing diagnostic precision.</p><p><strong>Conclusion: </strong>Our results indicate that SEResNet101 offers a promising enhancement over existing screening methods, integrating advanced deep learning algorithms to significantly improve the precision of cervical lesion classification. This study advocates for the inclusion of SEResNet101 in clinical workflows to enhance cervical cancer screening protocols, thereby improving patient outcomes. Future work should focus on multicentric trials to validate these findings and facilitate widespread clinical adoption.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"963"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.","authors":"Changsong Wang, JingChang Chen, Xuexia Lv, Tian Yun, Yaxi Wang, Nianlong Meng, Fulin Li, Yansha Cao, Naijun Fan, Xiaoyue Wang","doi":"10.1186/s12885-025-14374-8","DOIUrl":"https://doi.org/10.1186/s12885-025-14374-8","url":null,"abstract":"<p><p>The Ki-67 index, which is a proliferative index, has become more important in making treatment decisions for patients with breast cancer (BC) and plays both a predictive role and a prognostic role. However, a few factors limit its use in clinical practice, particularly the assessment of the percentage of Ki-67-positive cells and the cutoff value of Ki-67. In this study, we examined the expression of Ki-67 via immunohistochemistry and systematically evaluated the value of the Ki-67 index in patients with BC. This was a retrospective study including 280 patients diagnosed with BC. There were marked differences in overall survival (OS) between patients with BC when the Ki-67 index ranged from 46 to 68% (χ2 = 5.87, P = 0.0154; χ2 = 7.64, P = 0.0057, respectively), and the same results were also found when the staining density was added to the Ki-67 index; however, the staining density alone has limited value in assessing the value of Ki-67. There were marked differences in disease-free survival (DFS) among BC patients when the Ki-67 index ranged from 50 to 58% (χ2 = 7.31, P = 0.0069; χ2 = 7.88, P = 0.005). When 14% was used as a cutoff point to classify the molecular type of BC, the luminal A-type patients were significantly different from patients with HER2-overexpressing subtype BC in terms of OS (χ2 = 5.33, P = 0.021). There was a significant difference in the OS of patients with human epidermal growth factor receptor 2 (HER-2)-overexpressing subtype BC when the Ki-67 index fell within the range of 49-60% (χ2 = 4.86, P = 0.0275; χ2 = 5.50, P = 0.019, respectively). There were significant differences between luminal A-type BC and HER2-overexpressing subtype BC in terms of OS (χ2 = 5.53, P = 0.019), according to suggestions of the 2019 CSCO consensus. There were significant differences between the two groups of luminal B HER-2(-) BC when the Ki-67 index was 52% (χ2 = 6.61, P = 0.0101). The differentiated Ki-67 index can be used to assess the OS and DFS of patients with BC, and the staining density of Ki-67 has little value in assessing prognosis in these patients. Different molecular classification methods may influence the assessment of prognosis and the results of molecular subtype in patients with BC. To predict the prognosis of BC patients, it is more scientifically feasible to use the interval values of Ki-67 than a specific value.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"962"},"PeriodicalIF":3.4,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China.","authors":"Benlong Yang, Zhengkui Sun, Quchang Ouyang, Zhongsheng Tong, Shu Wang, Hongyuan Li, Zhaofeng Niu, Yiding Chen, Lin-Xiaoxi Ma, Haoqi Wang, Mu Tang, Zheyu Hu, Xueqiang Gao, Xu Wang, Fei Xie, Qiao Cheng, Yong Shen, Cuizhi Geng, Haibo Wang, Jiong Wu","doi":"10.1186/s12885-025-14223-8","DOIUrl":"10.1186/s12885-025-14223-8","url":null,"abstract":"<p><strong>Background: </strong>To investigate the treatment pattern, adverse events, and quality of life of Chinese patients treated with CDK4/6 inhibitors (CDK4/6i) for hormone receptor (HR)+/HER2- advanced breast cancer.</p><p><strong>Methods: </strong>This multicenter cross-sectional survey enrolled patients with HR+/HER2- advanced breast cancer currently treated with CDK4/6i. The patients reported adverse events and quality of life during CDK4/6i treatment with a questionnaire and EORTC QLQ-BR23. Meanwhile, the oncologists collected the treatment information, adverse events and patient characteristics from medical record.</p><p><strong>Results: </strong>The analysis included 1254 patients. Most patients received only one CDK4/6i, of which 38.92% received dalpiciclib, 35.81% received abemaciclib, 15.07% received palbociclib, and 0.47% received ribociclib, while 9.73% patients were treated with two CDK4/6i sequentially. The oncologists reported adverse events occurred in > 81.17% of patients, and most common AEs were leukopenia (63.30%) and neutropenia (58.73%). The most common symptomatic adverse events reported by the patients were fatigue (34.13%), alopecia (14.02%) and weakness (11.30%). The incidence of alopecia in patients receiving dalpiciclib was lower than in those receiving palbociclib (8.81% vs. 16.40%, P < 0.001) and abemaciclib (8.81% vs. 19.82%, P = 0.027). Regard to quality of life, breast symptom scores were lower in the palbociclib group than in the abemaciclib group (3.84 ± 8.57 vs. 5.70 ± 9.81, P = 0.047). Patient reported alopecia was associated with body image, systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss (all P < 0.001).</p><p><strong>Conclusions: </strong>The safety profile of different CDK4/6i varies and has different impacts on patients' quality of life, which needs more attention in clinical practice.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"951"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.","authors":"Haiyan Chen, Yaner Yu, Shuangqiu Zhu, Jian Zhao, Yan Ma, Zhifei Huang, Hao Jiang, Qichun Wei","doi":"10.1186/s12885-025-14278-7","DOIUrl":"https://doi.org/10.1186/s12885-025-14278-7","url":null,"abstract":"<p><strong>Background: </strong>Patient conditions including metabolic and nutritional status were reported to be prognostic or predictive biomarkers of anti-cancer treatment, while little attention has been paid to its association with the synergistic effect of radiotherapy (RT) and immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>Metastatic non-small-cell lung cancer (mNSCLC) patients who received concurrent RT and ICIs between 2018 and 2023 were included in this study. In addition, mNSCLC patients treated with ICIs alone were enrolled to confirm the synergetic effect of RT and ICIs. Clinicopathological, metabolic and nutritional factors were collected to analyze their influence on progression-free survival (PFS), overall survival and abscopal control time. Abdominal CT was used to obtain body composition data including abdominal obesity and muscle mass.</p><p><strong>Results: </strong>A total of 96 mNSCLC patients who received RT concurrent with ICIs were included, and a synergistic effect of significantly improved PFS was observed when compared with patients treated with ICIs alone. Among patients undergoing concurrent RT and ICIs, both total adipose area(HR = 2.81,P = 0.029) and prognosis nutritional index (HR = 0.24, P<0.001) were confirmed as independent positive prognostic markers for PFS. Later-line of immunotherapy (HR = 3.67, P = 0.006), low visceral-to-subcutaneous ratio (VSR, HR = 5.53, P = 0.002), high total adipose area (HR = 5.21, P = 0.0016) and high prognostic nutritional index (HR = 0.24, P = 0.002) were independent risk factors for abscopal progression. Then, we established a scoring system consisting of metabolic and nutritional factors to stratify patients into three groups. Patients with non-visceral obesity and good nutrition status have the longest PFS and abscopal control survival, while patients with poor nutritional status regardless of body composition represent the worst prognosis.</p><p><strong>Conclusion: </strong>Metabolic and nutritional status, particularly the combined assessment of body composition and nutritional index, serves as a valuable predictor for the synergistic efficacy of concurrent RT and ICIs.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"948"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory/recurrent brain tumors.","authors":"Hamid Mahdizadeh, Amirhossein Izadpanah, Yasaman Nouri, Parisa Shams, Delbar Daneshjou, Alireza Aziz Ahari, Alireza Tabibkhooei, Hamidreza Haghighatkhah, Massoud Vosough, Pooya Faranoush, Masoumeh Azimi, Saba Yousefi, Atefeh Barzegari, Alireza Khosravani, Niloufar Shayan Asl, Mohammad Faranoush, Marzieh Ebrahimi","doi":"10.1186/s12885-025-14314-6","DOIUrl":"10.1186/s12885-025-14314-6","url":null,"abstract":"<p><strong>Background: </strong>Pediatric glioma is a rare condition that can lead to significant mortality and morbidity due to its high recurrence rate. This study is a phase I nonrandomized clinical trial that was conducted to assess the safety, feasibility, and potential efficacy of the intrathecal (IT) injection of multiple doses of allogenic NK cells in pediatric patients with refractory/recurrent gliomas.</p><p><strong>Methods: </strong>Allogeneic NK cells were isolated from random healthy unrelated donors via positive selection of CD56 + cells. Nine patients were selected according to the inclusion criteria and received weekly doses of up to 10 doses of 5 × 10⁷ NK cells/injection. Adverse events grading was done based on Common Terminology Criteria for Adverse Events (CTCAE) Check lists. The size of the tumor, degree of spinal spreading and duration of relapse during 18 month followup were considered components of efficacy. Additionally, six patients who received conventional treatment were selected retrospectively.</p><p><strong>Results: </strong>Multiple intrathecal injections of allogeneic NK cells in pediatric gliomas were safe, without any serious adverse events (SAEs). The most prevalent AEs were headache [29% (17% grade 1 and 13% grade 2)], fever and chills [21% (17% grade 1 and 4% grade 2)], vomiting [13% grade 2], and back pain [12% (4% grade 1 and 8% grade 2)]. 18 months of follow-up, among the five patients in the intervention group who were still alive (August 7, 2024), three exhibited stable disease (SD), one had progressive disease (PD), and one experienced a partial response (PR) with a reduction in tumor size. Among the four deceased patients, two died due to tumor progression, and two died due to infections. In the retrospective control group, five out of six patients developed PD and leptomeningeal spread (LMS), four of whom died, and one patient showed radiological evidence of a complete response (CR). Cerebrospinal fluid (CSF) analysis revealed increases in the percentages of NK and T cells and significant reductions in the levels of IFN-γ and TNF-α.</p><p><strong>Conclusions: </strong>Multiple intrathecal injections of allogeneic NK cells are safe and feasible in pediatric patients with refractory/recurrent gliomas. Although we reported a reduction in recurrence episodes and an increase in overall survival, further studies with extended follow-up periods and appropriate control groups are necessary to assess the efficacy of NK cell therapy in these patients.</p><p><strong>Trial registration: </strong>The trial was registered on the Iranian Registry of Clinical Trials (IRCT20170122032121N6), Date 2021-11-19.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"952"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adequacy of pain management among advanced cancer patients with solid tumors attending palliative care centers in Dar es Salaam.","authors":"Judith Mwijage, Willbroad Kyejo, Davis Rubagumya, Thabit Kombo, Blessing Mathew, Faisal Hooda, Mandela Makakala, Eunice Pallangyo, Harrison Chuwa","doi":"10.1186/s12885-025-14385-5","DOIUrl":"https://doi.org/10.1186/s12885-025-14385-5","url":null,"abstract":"<p><strong>Background: </strong>Cancer pain presents a universal challenge for patients and their families, significantly impacting quality of life. While observational studies suggest an increase in palliative care programs in Tanzania, the adequacy of pain control for cancer patients remains underexplored. Addressing this gap is crucial for enhancing patient well-being and care quality.</p><p><strong>Methodology: </strong>This analytical cross-sectional study, conducted from October to December 2021 in Dar es Salaam, Tanzania, involved 332 advanced cancer patients with solid tumors from the Aga Khan Hospital and Ocean Road Cancer Institute. A structured, interviewer-administered questionnaire comprising demographic data and factors influencing cancer-related pain (CRP) management was utilized. Additionally, the Brief Pain Inventory Short Form (BPI-SF) assessed pain intensity and interference. Statistical analysis, including chi-square tests and logistic regression, was performed using SPSS version 25 to evaluate factors associated with adequate CRP management.</p><p><strong>Results: </strong>Among 332 participants, 199 (59.9%) experienced adequate pain management, with prevalence notably higher among females, patients from Aga Khan Hospital, divorced, employed, and tertiary-educated individuals. Multivariable analysis identified sex, employment status, and education level as significant predictors of adequate pain management, with females having twice the likelihood of adequacy compared to males (OR: 1.96; 95%CI: 1.06-3.66; p = 0.033). Self-employed participants had significantly lower odds of adequate pain management compared to the employed (OR = 0.08; 95%CI: 0.01-0.33; p = 0.002), while unemployment was associated with a 91% lower likelihood of adequacy (OR = 0.09; 95%CI: 0.01-0.42; p = 0.006). Furthermore, individuals with primary education were 2.47 times more likely to report adequate pain management compared to those with nonformal education (OR: 2.47; 95%CI: 1.16-5.43; p = 0.021).</p><p><strong>Conclusion: </strong>The study highlights inadequate CRP management in Tanzania and emphasizes the influence of patient-related factors such as sex, employment status, and education level. These findings underscore the importance of tailored interventions to address disparities and enhance pain management strategies for cancer patients. Efforts to improve CRP management should consider sociodemographic factors to optimize care delivery and alleviate patient suffering effectively.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"949"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term impact of delayed surgical treatment on the prognosis of patients with T1bN1-stage PTC: a retrospective cohort study.","authors":"Hao Gong, Tianyuchen Jiang, Yi Yang, Yuhan Jiang, Zhujuan Wu, Anping Su","doi":"10.1186/s12885-025-14371-x","DOIUrl":"https://doi.org/10.1186/s12885-025-14371-x","url":null,"abstract":"<p><strong>Background: </strong>As the incidence of papillary thyroid carcinoma (PTC) increases, optimal timing for surgical interventions remains undefined. While surgical delays are known to affect prognosis adversely in various cancers, their impact on PTC is controversial.</p><p><strong>Methods: </strong>A retrospective study was conducted on 478 T1bN1-stage PTC patients treated at West China Hospital from January 2020 to May 2022. Patients underwent thyroidectomy with lymph node dissection and were categorized into three groups based on surgical delay: ≤90 days (group A, n = 264), > 90-180 days (group B, n = 92), and > 180 days (group C, n = 122). Additionally, patients were reclassified into two groups based on a one-year threshold: ≤365 days (group D, n = 420) and > 365 days (group E, n = 58). Tumor metastasis rates and postoperative complications were analyzed across these groups.</p><p><strong>Results: </strong>The median surgical delay was 79 days, and the median follow-up was 1362 days. Tumor metastasis occurred in 1.67% (8 patients), while postoperative complications occurred in 5.65% (27 patients). Metastasis rates were 1.89%, 1.09%, and 1.64%, and complication rates were 5.68%, 4.35%, and 6.56% for groups A, B, and C, respectively. No statistically significant differences were observed in metastasis or complication rates among the three groups. Similarly, no significant differences were found between groups D and E in tumor metastasis (p = 1.000) or complication rates (p = 0.555).</p><p><strong>Conclusion: </strong>Delayed surgery was not associated with significantly increased short-term tumor metastasis or postoperative complication rates in patients with T1bN1-stage PTC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"950"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning network enhances imaging quality of low-b-value diffusion-weighted imaging and improves lesion detection in prostate cancer.","authors":"Zheng Liu, Wei-Jie Gu, Fang-Ning Wan, Zhang-Zhe Chen, Yun-Yi Kong, Xiao-Hang Liu, Ding-Wei Ye, Bo Dai","doi":"10.1186/s12885-025-14354-y","DOIUrl":"10.1186/s12885-025-14354-y","url":null,"abstract":"<p><strong>Background: </strong>Diffusion-weighted imaging with higher b-value improves detection rate for prostate cancer lesions. However, obtaining high b-value DWI requires more advanced hardware and software configuration. Here we use a novel deep learning network, NAFNet, to generate a deep learning reconstructed (DLR₁₅₀₀) images from 800 b-value to mimic 1500 b-value images, and to evaluate its performance and lesion detection improvements based on whole-slide images (WSI).</p><p><strong>Methods: </strong>We enrolled 303 prostate cancer patients with both 800 and 1500 b-values from Fudan University Shanghai Cancer Centre between 2017 and 2020. We assigned these patients to the training and validation set in a 2:1 ratio. The testing set included 36 prostate cancer patients from an independent institute who had only preoperative DWI at 800 b-value. Two senior radiology doctors and two junior radiology doctors read and delineated cancer lesions on DLR₁₅₀₀, original 800 and 1500 b-values DWI images. WSI were used as the ground truth to assess the lesion detection improvement of DLR₁₅₀₀ images in the testing set.</p><p><strong>Results: </strong>After training and generating, within junior radiology doctors, the diagnostic AUC based on DLR₁₅₀₀ images is not inferior to that based on 1500 b-value images (0.832 (0.788-0.876) vs. 0.821 (0.747-0.899), P = 0.824). The same phenomenon is also observed in senior radiology doctors. Furthermore, in the testing set, DLR₁₅₀₀ images could significantly enhance junior radiology doctors' diagnostic performance than 800 b-value images (0.848 (0.758-0.938) vs. 0.752 (0.661-0.843), P = 0.043).</p><p><strong>Conclusions: </strong>DLR₁₅₀₀ DWIs were comparable in quality to original 1500 b-value images within both junior and senior radiology doctors. NAFNet based DWI enhancement can significantly improve the image quality of 800 b-value DWI, and therefore promote the accuracy of prostate cancer lesion detection for junior radiology doctors.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"953"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}